Anna DeFazio

ORCID: 0000-0003-0057-4744 · 27 papers in corpus
review 2016
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as wit…

observational 2014
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.epi-13-0962

Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-κB (NF-κB) transcription factor fam…